Navigation Links
Genoptix Reports Strong Financial Results for the Fourth Quarter and Full Year 2007
Date:2/12/2008

as filed with the United States Securities and Exchange Commission on February 12, 2008. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Genoptix undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they were made, or to reflect the occurrence of unanticipated events.

[Financial tables follow]

GENOPTIX, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands)

December 31,

2007 2006

Assets

Current assets:

Cash and cash equivalents $50,624 $3,865

Investment securities available-for-sale 34,836 -

Accounts receivable, net of allowance for

doubtful accounts 9,013 4,766

Other current assets 1,409 270

Total current assets 95,882 8,901

Property and equipment, net 1,950 1,287

Other long-term assets - 14

Total assets $97,832 $10,202

Liabilities and Stockholders' Equity

Current liabilities:

Accounts payable and accrued expenses $4,312 $1,987

Accrued compensation 2,496 1,058

Deferred revenue 95 39

Current portion of long-term debt - 1,524

Total current liabilities 6,903 4,608

Deferred rent
'/>"/>

SOURCE Genoptix, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Genoptix, Inc. to Announce Fourth Quarter and Full Year 2007 Financial Results on February 12, 2008
2. Genoptix, Inc. Announces Pricing for Initial Public Offering
3. MIB Life Index Reports North American Life Insurance Activity Up 1.4% in December
4. NxStage Medical Reports Fourth Quarter and Full Year 2007 Results
5. Nutrition 21 Reports Fiscal Second Quarter 2008 Financial Results
6. Mesa Labs Reports Higher Quarterly Sales and Earnings
7. Triple-S Management Corporation Reports Record Consolidated Operating Income, Net Income and EPS for 2007
8. Palatin Technologies, Inc. Reports Fiscal Year 2008 Second Quarter Results; Teleconference and Webcast to be held on February 11, 2008
9. LCA-Vision Reports Fourth Quarter and Full-Year 2007 Financial Results
10. Neurobiological Technologies Reports Second Quarter Financial Results
11. Hawkins, Inc. Reports Third Quarter, Nine Months Fiscal 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:Patriot Scientific Corporation Announces New Director 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 2Health News:Secure-24 and ATMP Consulting Group Launch Partnership for Private Practice Physicians to Meet IT and Electronic Medical Record Standards 3Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 2Health News:Washington Regional Partners with U.S. Preventive Medicine to Bring a New Level of Preventive Health Care Services to Northwest Arkansas 3Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 2Health News:Industry Coalition Reissues Advisory Against Use of Dietary Supplements as Swine Flu Remedy, Cure 3
Other Medicine News:Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 2Health News:Child mental health experts issue psychiatric medication treatment guidelines for preschoolers 3Health News:Aerosol launches immune response in lungs to wipe out lethal infections 2Health News:Aerosol launches immune response in lungs to wipe out lethal infections 3Health News:Lymphatic vessel and lymph node function are restored with growth factor treatment 2Health News:Lymphatic vessel and lymph node function are restored with growth factor treatment 3Health News:Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008 2Health News:Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008 3Health News:Rosetta Genomics Strengthens Senior Management in Preparation for its First Commercial Launch of microRNA-Based Diagnostic Products in 2008 4Health News:Alfacell to Host Fiscal First Quarter 2008 Financial Results Conference Call and Webcast 2Health News:Superior Dental Care Alliance Launches Maximum Advantage Program 2
Breaking Medicine Technology:ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 2ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 3ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 4ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 5ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 6ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease 7Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 1Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 2Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 3Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 4Health Leaders Issue Recommendations to Improve Management of a Common Costly and Misunderstood Cardiovascular Disease 3A Atrial Fibrillation 57357 5Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 1Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 2Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 3Abbott Expands Use of Sustainable Packaging as Part of Global Environmental Efforts 57353 4Experts to Highlight Key Trends in Physician and Healthcare Executive Recruitment Leadership and Compensation 57349 1Experts to Highlight Key Trends in Physician and Healthcare Executive Recruitment Leadership and Compensation 57349 2Experts to Highlight Key Trends in Physician and Healthcare Executive Recruitment Leadership and Compensation 57349 3